Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.